VALNEVA news, videos and press releases - Page 6
For more news please use our advanced search feature.
VALNEVA - More news...
VALNEVA - More news...
- Valneva Announces Publication in The Lancet of Complete Phase 1 Data for its Single-Shot Chikungunya Vaccine Candidate
- Valneva Announces the Availability of Documentation for its Closed-Door Combined General Meeting
- Valneva Reports Q1 Results and Updates 2020 Guidance Following Major Lyme Partnering Deal
- Valneva - Déclaration d’actions et de droits de vote Avril 2020 / Déclaration d’actions et de droits de vote rectificative Mars 2020
- Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
- Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 Study
- Valneva Reports Record Product Sales and Major Pipeline Progress in 2019
- Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed
- Valneva: US DoD Exercises Option on IXIARO® Supply Contract Bringing Total Value to $70 Million
- Valneva Expands its Commercial Operations with the Opening of its French Commercial Office
- Valneva Completes Delisting from the Vienna Stock Exchange
- Valneva Appoints MVM Partner Thomas Casdagli to its Supervisory Board
- Valneva Raises Product Sales Guidance Following Strong Nine-Month Results and R&D Execution
- CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine
- Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15
- Valneva Shareholders Approve all Resolutions Recommended by the Management Board at the Annual General Meeting
- VALNEVA Reports Further Positive Results for Its Chikungunya Vaccine Candidate
- VALNEVA Reports Strong Q1 2019 Operating Results and Advances Key R&D Programs towards Major Milestones
- VALNEVA to Present on Lyme and Chikungunya Vaccine Candidates at the 19th World Vaccine Congress
- Ad hoc: Valneva Announces Termination of 2013 Shareholder Agreement
- VALNEVA Reports Strong 2018 Results, Expects Further Growth and Major Pipeline Progression in 2019
- VALNEVA Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate
- VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019
- VALNEVA Announces New $59 Million IXIARO® Supply Contract with US Government
- VALNEVA Announces its Intention to Delist from the Vienna Stock Exchange
- VALNEVA Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
- VALNEVA Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate
- VALNEVA Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
- VALNEVA and HOOKIPA Sign a Collaboration and Manufacturing Agreement
- VALNEVA to Conduct Investor and Partnering Meetings During the 37th Annual J.P. Morgan Healthcare Conference
